Top Markets
Coin of the day
Roquefort Therapeutics plc Roquefort Therapeutics plc

Roquefort Therapeutics plc

ROQ
Rank in Stocks #37956
Roquefort Therapeutics plc functions as a biotechnology firm, focusing its... Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.
Share Price
$0.10205262
Last synced: 2026-04-23
Market Cap
$1.32M
Change (1 day)
5.19%
Change (1 year)
-54.38%
Country
GB
Trade Roquefort Therapeutics plc (ROQ)

Category

P/B ratio for Roquefort Therapeutics plc (ROQ)
P/B ratio as of 2026 TTM: 0
According to Roquefort Therapeutics plc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Roquefort Therapeutics plc from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE